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Case Report

Subarachnoid transplantation of autologous neurogenically induced bone marrow
derived mesenchymal stem cells for the treatment of fibrocartilaginous embolic
myelopathy in two dogs
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Abstract: The objective of this study was to investigate the effects of autologous neurogenically induced bone marrow-derived
mesenchymal stem cells (NIBM-MSCs) in two dogs suspected to have fibrocartilaginous embolic myelopathy (FCEM). Both dogs were
paraplegic without deep pain perception (DPP) and tentatively diagnosed by MRI. Autologous NIBM-MSCs (5 × 106) were transplanted
into the lumbar subarachnoid space two times with a 21-day interval for each patient. Based on a 21-month follow-up of the treated
animals, the transplantation of NIBM-MSCs seems to be promising in subjects with FCEM lacking DPP.
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1. Introduction
Fibrocartilaginous embolic myelopathy (FCEM) is a
disease commonly seen in dogs that causes an acute
spinal cord infarction due to occlusion of spinal vessels
by incoming fibrocartilaginous material from the nucleus
pulposus of the intervertebral disk in different suspected
ways (1,2). Although a certain diagnosis of FCEM can be
confirmed by histopathologic examination, the typical
clinical presentation (peracute, nonprogressive after 24 h,
without pain, and usually with asymmetric myelopathy)
and the exclusion of other causes with diagnostic imaging
and CSF analysis can provide antemortem diagnosis (3).
The treatment of dogs with ischemic myelopathy is still
controversial. The use of corticosteroids during the acute
phases has been suggested by some authors, though the
beneficial effect of methylprednisolone in human patients
with acute spinal cord injury is not clear. Physiotherapy is
thought to have a role in stimulating neuronal plasticity
and its benefits in dogs with ischemic myelopathy have
been described (2). Recently the beneficial effects of
different types of stem cell therapy for neural regeneration
in human and veterinary medicine have gained attention.
The positive effects of human umbilical cord derived
mesenchymal stem cells have been reported in one dog
with FCEM (4).
* Correspondence: besalti@hotmail.com
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The aim of the present study was to report the effects
of subarachnoid injections of autologous neurogenically
induced bone marrow-derived mesenchymal stem cells
(NIBM-MSCs) in two dogs with paraplegia secondary to
FCEM (tentatively diagnosed through MRI and clinical
signs) and lacking deep pain perception (DPP).
2. Case history
One of the dogs (case 1) was a 5-year-old Dachshund male
intact dog with acute onset paraplegia without DPP for 2
days. The other dog (case 2) was a 2-year-old female mixed
breed intact dog with acute onset paraplegia without DPP
for 3 days. According to the history of both cases, the
clinical signs were not progressive or symmetric.
In the neurologic examination the Texas spinal cord
injury score was obtained to evaluate the neurologic score
at the time of admission and to evaluate the outcomes
(5). The segmental spinal reflexes and standard spinal
radiographs were normal. The results of CSF analysis were
unremarkable in both dogs.
The images of all cases were obtained with an MRI
unit (Siemens superconducting magnet, field strength of
1.5 tesla, Siemens AG, Germany), using a spinal coil. T1
weighted images (TR: 370–700 ms, TE: 15–20 ms) and
T2 weighted images (TR: 2000–4000 ms, TE: 90–110 ms)
were adjusted to 2-mm slice thickness.
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Physiotherapy, including active range of motion
massage to the hindlimbs and warming the thoracolumbar
spine and hindlimbs, and forcing the dog to stand and walk
with bellyband were recommended to the owners during
the processing period of collecting bone marrow cells and
also following transplantation.
Bone marrow was collected from the iliac crest and
transported to the laboratory within 1 h. BM-MSCs were
cultured according to standard methods (6). The cells
were cultured up to passage 2 and ~5.0 × 106 BM-MSCs
were separated and induced into the neurogenic lineage.
The remaining BM-MSCs were cultured likewise for the
subsequent booster application. BM-MSCs were induced
into the neurogenic lineage by a two-step differentiation
protocol (7). Immunohistochemistry revealed that these
cells were positive for CNPase and MAP-2, as well as for
GFAP and beta III tubulin (Abcam). The autologous NIBMMSCs were transplanted into the L5–6 subarachnoid space
two times for each case with a 21-day interval.
3. Results and discussion
In case 1, neurological examination upon admission
revealed that the Texas gait score was 1 (intact limb
protraction with no ground clearance), but both
proprioception and nociception scores were absent (0)
and the clinical signs were symmetric. Hyperintense
focal unshaped and asymmetric lesions in the spinal
cord parenchyma at the level of T12–L1 in T2 w images,
and hypoisointense lesions in T1 w images in MRI were
observed. There were also type 2 disk degenerations in the
T13–L1 and L1–2 regions. The lesion length (62 mm)/L2
length (17.4 mm) ratio was 3.56 and the percent crosssectional area was about 52.46% in T2 w images. Prior to
transplantation of stem cells (42 days after admission) the
neurological status was the same as it was upon admission.
In case 2, neurological examination at the time of
admission revealed that the Texas walking score was the
same as in case 1. A hyperintense focal asymmetric lesion
in the spinal cord parenchyma at the level of T11 on T2 w
FSE images, and a hypoisointense lesion in T1 w images
in MRI were observed (Figures 1 and 2). No sign of disk
extrusion or protrusion was seen. The lesion length (28.65
mm)/L2 length (21.1 mm) ratio was about 1.36 and the
percent cross-sectional area was about 60% (4.26/7.14).
Prior to transplantation of stem cells (42 days after
admission) the neurologic status was as follows: gait score
of 3 (intact protraction with ground clearance in more
than 75% of the steps), proprioception of 1 (delayed), and
nociception of 1 (deep nociception present).
The neurological status of the Dachshund 2 weeks after
the second stem cell injection showed no changes. In the
mixed breed dog 1 score improvement was seen in the gait
and proprioception scores. At 18 months after treatment,

Figure 1. Hyperintense asymmetric lesion in the spinal cord
parenchyma at the level of T11 on sagittal T2 w images in the
mixed breed dog.

Figure 2. Hyperintense asymmetric lesion in the spinal cord
parenchyma at the level of T11 on transversal T2 w images in the
mixed breed dog.

the mixed breed dog had fully recovered neurologically,
while the Dachshund had the same proprioception score.
At 21 months after treatment, the Dachshund improved
totally except for a proprioception score of 1 (delayed).
To the authors’ knowledge, this is the first report of
using autologous NIBM-MSCs for the treatment of FCEM
in dogs. The results of the present study provide reasons for
optimism in the treatment of ischemic spinal cord injury.
Characteristic MRI findings are among the most
important tools in the differential diagnosis of extradural
myelopathy and in defining intraparenchymal lesions
(3,8). The outcome has been associated with the extent
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of the ischemic intramedullary lesion on MRI, defined
as the ratio between the length of the intramedullary
hyperintensity on midsagittal T2-w images and the length
of the vertebral body (referred to as the lesion length–L2
vertebral length ratio) and as the cross-sectional area of
the largest intramedullary hyperintensity on transverse
T2-w images expressed as a percentage of the crosssectional area of the spinal cord at the same level (referred
to as percent cross-sectional area of the lesion). Dogs with
a lesion length–vertebral length ratio greater than 2.0,
or with a cross-sectional area of the lesion (transversal
images) of 67% or greater, are significantly more likely
to have an unsuccessful outcome than those with lower
values for these parameters. The values of our mixed breed
dog were close the lower limits; however, the values of the
Dachshund dog were higher. When the outcome period
is considered, the results of the 2 cases were in line with a
previous report (3).
The prognosis of FCEM depends on the loss of
nociception, symmetric neurologic deficits, the severity
of neurologic signs at initial examination quantified
by a neurologic score, and the lack of spontaneous
improvement within the first 14 days (1–3). The outcome
has also been associated with the extent of the ischemic
intramedullary lesion, and different recovery rates have
been reported (3,9).
The two cases were presented with nonambulatory
paraplegia without DPP, and had not been medicated
before; they were subjected to cell therapy since their
prognoses were evaluated as poor. While one case
showed some improvement with just physical therapy
on day 42 after admission, the other case did not
show any improvement in the same period. The main
difference between these two dogs was that the slowerimproving dog was chondrodystrophic and had some
type 2 disk degeneration as well. Mostly the dogs with
confirmed FCEM are nonchondrodystrophic breeds
and are rarely chondrodystrophic. The nucleus matrix
of nonchondrodystrophic breeds remains soft and
gelatinous during a longer period of time compared
with that of chondrodystrophic breeds (1,10). Although
both cases reported in the present study were not

evaluated histologically, FCEM diagnosis was strongly
suspected. The presence of type 2 disk disease without any
compression complicated our tentative diagnosis, but the
intraparenchymal hyperintensity and clinical signs could
not be explained by disk disease alone. The unremarkable
CSF results differentiated the disease from granulomatous
meningoencephalomyelitis.
The treatment of dogs with ischemic myelopathy is
controversial and there is no specific treatment (1,3).
Recently, the clinical application of spinal cord regenerative
therapy using BM-MSCs has led to promising results in
human and veterinary medicine. Bone marrow stromal
cells have the ability to migrate to the site of CNS injury
following intravascular or intrathecal administration
(11). When predifferentiated MSCs are expanded and
differentiated into neurospheres in vitro, before being
transplanted back, they may prove to be more beneficial
for treating SCI (4). Booster transplantation of autologous
NIBM-MSCs was carried out to extend the therapeutic
effects of cells on the release of cytokines and on the
possibility of extending the cell replacement period. The
beneficial effect of autologous bone marrow-derived MSC
transplantation in naturally occurring SCI was reported
(12). The use of neurogenically induced allogeneic MSCs
was also studied in experimentally induced spinal cord
injury with promising results (13). We think that inducing
autologous MSCs is more useful for SCI, except for the
time needed for cell processing. However, cell therapy in
the acute stage of the disease did not produce useful effects
in the two cases studied.
Based on the findings of the present study, the use
of autologous NIBM-MSCs seems to be a promising
treatment modality for cases with guarded prognosis of
FCEM embolic myelopathy in dogs. Further qualified
clinical studies are needed to confirm the outcome of this
treatment method.
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